Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 4/20 | 0.37 |
| ▸ | IRAK4 | Q9NWZ3 | 7/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.34 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.32 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.32 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.32 |
| ▸ | CDK2 | P24941 | 1/20 | 0.32 |
| ▸ | CDK9 | P50750 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3372625 | 0.78 | GRM5 (0.40) | CCR1IRAK4MCHR1MEN1POLB | |
| SCHEMBL3405834 | 0.76 | MCHR1 (0.32) | MAPTIRAK4ALDH1A1MCHR1GRIN3B | |
| SCHEMBL13739153 | 0.76 | MCHR1 (0.60) | CCR1CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL3372661 | 0.75 | MAPT (0.44) | CYP1A2MAPTCYP2C19ALDH1A1MEN1 | |
| SCHEMBL3375305 | 0.75 | MAPT (0.44) | CYP1A2MAPTCYP2C19ALDH1A1MEN1 | |
| SCHEMBL13737374 | 0.73 | CCR1 (0.52) | CCR1CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL12068249 | 0.73 | CCR1 (0.67) | CCR1MAPTFGFR4ALDH1A1MEN1 | |
| SCHEMBL30262339 | 0.71 | CYP1A2 (0.45) | CCR1CYP1A2MAPTCYP2C9CYP2C19 | |
| SCHEMBL3373060 | 0.71 | MAPT (0.35) | MAPTALDH1A1MEN1POLBKMT2A | |
| SCHEMBL13738235 | 0.71 | CCR1 (0.44) | CCR1CYP1A2MAPTCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101155808-B | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE | 2011-08-31 | — | — | CN | disclosed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| EP-1869036-B1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2010-11-03 | — | — | EP | disclosed |
| CN-101155808-A | Substituted 1,5-naphthyridine azolidinones as cdk inhibitors | HOFFMANN LA ROCHE (CH) | 2008-04-02 | — | — | CN | disclosed |
| EP-1869036-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. Hoffmann-Roche AG (CH) | 2007-12-26 | — | — | EP | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| US-7304074-B2 | Substituted 1,5-naphthyridine azolinones | HOFFMANN-LA ROCHE INC. (US) | 2007-12-04 | — | — | US | disclosed |
| WO-2006106046-A1 | SUBSTITUTED 1,5-NAPHTHYRIDINE AZOLIDINONES AS CDK INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-10-12 | — | — | WO | disclosed |
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | LIU JIN-JUN | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223843-A1 | Substituted 1,5-naphthyridine azolinones | CDK4, CDK1, CDK14 | CCR1 3897/4885CYP1A2 1474/4885MAPT 2888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.